| PlayDecide

Polka Project Workshop Seriese

Policy
1	Since resources are limited, there should be a limit and only cost effective drugs that benefit the greater number of patients should be reimbursed. If a drug purchaser has to choose between treating 10 patients with drug A or 1 with drug B for a rare disease, then the choice should always be to treat 10 with drug A.
2	Only cost effective drugs should be reimbursed, but the approach for orphan drugs should be different than for common diseases. If there is any doubt about the cost effectiveness of an orphan drug, it should be exceptionally reimbursed in certain cases.
3	Like position 2, but if there is any doubt about the cost effectiveness of an orphan drug, the benefit of doubt should be given to the patient and the drug should be reimbursed systematically.
4	Health is a priority for European citizens. Just as efforts to rescue people after an accident are not restricted, efforts to rescue a patient with a rare disease should not be limited. Cost effectiveness should not be the parameter on which to base reimbursement decisions.

Overview of the new policies developed by players in this event.




National regulation defines along EU regulation principles what tests for what kind of purposes should be available and if it is not available in the country where can the patients go for the necessary examinations. The patients must be informed by health care professionals about their further possibilities. This process should be based on a EU database. The patient has the right to decide when and what kind of tests will be done.
After being judged individually it could be performed with sctrict supervision on those genetical deseases have not determinated previously.

Like position 2, but if there is any doubt about the cost effectiveness of an orphan drug, the benefit of doubt should be given to the patient and the drug should be reimbursed systematically according to a personal budget.
The goverment invest in some e-healthcare development, and creats the emergecy system with reimbursing the fees for the patient and for his one accompany.
The goverment should reimburse the fees for the patient and his accompany where appropriate, and should take care of the e-healthcare.